[go: up one dir, main page]

CO4990972A1 - Derivados de eritromicina en puente 6,11 - Google Patents

Derivados de eritromicina en puente 6,11

Info

Publication number
CO4990972A1
CO4990972A1 CO98062727A CO98062727A CO4990972A1 CO 4990972 A1 CO4990972 A1 CO 4990972A1 CO 98062727 A CO98062727 A CO 98062727A CO 98062727 A CO98062727 A CO 98062727A CO 4990972 A1 CO4990972 A1 CO 4990972A1
Authority
CO
Colombia
Prior art keywords
group
substituted
absent
aryl
hydrogen
Prior art date
Application number
CO98062727A
Other languages
English (en)
Inventor
Yat Sun Or
Li Leping
Daniel T Chu
George W Griesgraber
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO4990972A1 publication Critical patent/CO4990972A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un compuesto seleccionado del grupo que consiste de:en dondem es 0, 1, 2, 3, 4, 5, 6, o 7;n es 0, 1, 2, 3 o 4;Rp es independientemente hidrógeno o un grupo protector hidroxi cada vez que ocurre;A está ausente o es seleccionada del grupo que consiste de(1) -O-, y(2) -N(R1 )-, en donde R1 es hidrógeno o alquil- C1 -C6 opcionalmente substituido con arilo oheteroaril;B está ausente o es seleccionado del grupo que consiste de(1) -(CH2 )q -, en donde q es 0, 1, 2, 3, 4, 5 o 6,(2) -C(O)-(CH2 )q -,(3) -C(O)-O-(CH2 )q -,(4) -C(O)-NR1 -(CH2 )q -, donde R1 es como se definió previamente, y(5) -N=CH-(CH2 )q -,(6) -CH(OH)-(CH2 )q -, y(7) -CH(OH)-CH(OH)-(CH2 )q -;D está ausente o es seleccionado del grupo que consiste de(1) alquenileno,(2) arileno,(3) arileno substituido por reemplazo independiente de uno, dos o tres de los átomos de hidrógeno con halo, hidroxi, ciano, alquil C1 -C3 , alcoxi C1 -C6 , alcoxi C1 -C6 substituido con aril, haloalquil, tioalcoxi, amina, alquilamina, dialquilamina, mercapto, nitro, carboxaldehído, carboxi, alcoxicarbonil y carboxamida. Adicionalmente cualquier substituyente puede ser un grupo aril, heteroaril o heterocicloalquil,(4) heteroarileno,(5) heteroarileno substituido por reemplazo independiente de uno, dos o tres de losátomos de hidrógeno con Cl, Br, F, I, OH, CN, ...
CO98062727A 1997-10-29 1998-10-27 Derivados de eritromicina en puente 6,11 CO4990972A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96040097A 1997-10-29 1997-10-29
US15826998A 1998-09-22 1998-09-22

Publications (1)

Publication Number Publication Date
CO4990972A1 true CO4990972A1 (es) 2000-12-26

Family

ID=26854886

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98062727A CO4990972A1 (es) 1997-10-29 1998-10-27 Derivados de eritromicina en puente 6,11

Country Status (23)

Country Link
EP (1) EP1027361B1 (es)
JP (1) JP2001521038A (es)
KR (1) KR20010031591A (es)
CN (1) CN1278266A (es)
AR (1) AR015986A1 (es)
AT (1) ATE239750T1 (es)
AU (1) AU1286799A (es)
BG (1) BG104425A (es)
BR (1) BR9813317A (es)
CA (1) CA2307828A1 (es)
CO (1) CO4990972A1 (es)
DE (1) DE69814441T2 (es)
DK (1) DK1027361T3 (es)
ES (1) ES2198766T3 (es)
HU (1) HUP0004323A2 (es)
IL (1) IL134996A0 (es)
NO (1) NO20002099L (es)
PL (1) PL340253A1 (es)
PT (1) PT1027361E (es)
SK (1) SK6342000A3 (es)
TR (1) TR200001140T2 (es)
TW (1) TW486485B (es)
WO (1) WO1999021864A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437106B1 (en) * 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
US6472372B1 (en) * 2000-12-06 2002-10-29 Ortho-Mcneil Pharmaceuticals, Inc. 6-O-Carbamoyl ketolide antibacterials
JP2005503416A (ja) 2001-09-17 2005-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 6−o−カルバメート−11,12−ラクト−ケトライド抗菌剤
HUP0500018A3 (en) 2001-12-05 2009-09-28 Ortho Mcneil Pharm Inc 6-o-acyl ketolide derivatives of erythromycine processes for preparing them and using them as antibacterials
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
AU2003229037B8 (en) * 2002-05-13 2009-07-02 Enanta Pharmaceuticals, Inc. 6,11 bicyclic erythromycin derivatives
US7129221B2 (en) 2002-05-13 2006-10-31 Enanta Pharmaceuticals, Inc. 6,11-bicyclic erythromycin derivatives
US6753318B1 (en) 2002-07-25 2004-06-22 Enanta Pharmaceuticals, Inc. 6,11-4-carbon bridged erythromycin derivatives
US6841664B2 (en) 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US6645941B1 (en) * 2003-03-26 2003-11-11 Enanta Pharmaceuticals, Inc. 6,11-3C-bicyclic 9a-azalide derivatives
US7414030B2 (en) 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
WO2005070113A2 (en) 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
WO2005080408A1 (en) * 2004-01-23 2005-09-01 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US7384921B2 (en) 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
US7384922B2 (en) 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US7589067B2 (en) 2005-10-12 2009-09-15 Enanta Pharmaceuticals, Inc. 6, 11-bridged tricyclic macrolides
US8273720B2 (en) 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
WO2018201076A2 (en) * 2017-04-28 2018-11-01 Macrolide Pharmaceuticals Inc. Macrolides with modified desosamine sugars and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876388B1 (en) * 1995-11-08 2004-02-18 Abbott Laboratories Tricyclic erythromycin derivatives

Also Published As

Publication number Publication date
DK1027361T3 (da) 2003-08-25
CA2307828A1 (en) 1999-05-06
ATE239750T1 (de) 2003-05-15
NO20002099D0 (no) 2000-04-25
EP1027361B1 (en) 2003-05-07
HUP0004323A2 (hu) 2001-02-28
DE69814441D1 (de) 2003-06-12
NO20002099L (no) 2000-06-29
SK6342000A3 (en) 2000-09-12
AR015986A1 (es) 2001-05-30
TW486485B (en) 2002-05-11
BR9813317A (pt) 2000-08-22
DE69814441T2 (de) 2004-04-08
PL340253A1 (en) 2001-01-29
BG104425A (bg) 2001-01-31
AU1286799A (en) 1999-05-17
ES2198766T3 (es) 2004-02-01
JP2001521038A (ja) 2001-11-06
WO1999021864A1 (en) 1999-05-06
CN1278266A (zh) 2000-12-27
KR20010031591A (ko) 2001-04-16
TR200001140T2 (tr) 2001-05-21
EP1027361A1 (en) 2000-08-16
PT1027361E (pt) 2003-09-30
IL134996A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
CO4990972A1 (es) Derivados de eritromicina en puente 6,11
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
CO5060510A1 (es) Isotiazol carboxiamidas y composiciones para la proteccion de las plantas
ES2190129T3 (es) Agente auxiliar de cementacion.
ES2192520T3 (es) Composicion farmaceutica.
BRPI0506817A (pt) inibidores seletivos de quinase
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
CO5180568A1 (es) Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
RS50700B (sr) Biciklična heterociklična jedinjenja kao inhibitori hiv integraze
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
YU57603A (sh) Inhibitori fosfodiesteraze 4
CO5140110A1 (es) Nuevos antibioticos macrolidos
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .
TW200508359A (en) Quinoxaline derivatives, and light emitting element using thereof
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
TW200612920A (en) Novel imidazolidine derivatives
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
DE60011269D1 (de) Azaidole mit serotonin rezeptor affinität
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
CO5601030A2 (es) Derivados de quinolinona/benzoxazinona y usos de los mismos
DE69724646D1 (de) 16-ene-vitamin d derivate